| Followers | 374 |
| Posts | 5388 |
| Boards Moderated | 1 |
| Alias Born | 05/09/2013 |
Friday, July 29, 2016 12:33:13 PM
I decided to exit ORPN today (for a small profit) after I saw 1.70 level start to break down.
Ever since the 1.90's hit on Monday (while my original minimum target area has been 1.85+) it has been slowly breaking down all week ever since the highs Monday.
I tried to be as patient as possible looking for more upside, but it just isn't happening yet.
It is possible that this could still hold 1.53+ support lows from a few weeks ago, but I'm not going to stick around to see what happens, but instead take a small profit and move forward. This poses a high risk of dropping much lower again in the short term, so it is basically why I'm suggesting to exit this.
***I'm on the sidelines for the time being and will wait to see if another opportunity to enter lower happens on ORPN, along with soon looking at other stocks.
ORPN had earlier provided plenty of opportunity for good entry in 1.50's-1.60's area (with suggestion of 1.66 Limit entry) this weeks action, so anyone following should be able to scrape out with a profit or at least break even.
It's ironic how the LABU - biotech index has been tearing it up the last few weeks at the same time while ORPN has been sitting sideways with slight upside at the same time... Oh well---- that's trading.
Ever since the 1.90's hit on Monday (while my original minimum target area has been 1.85+) it has been slowly breaking down all week ever since the highs Monday.
I tried to be as patient as possible looking for more upside, but it just isn't happening yet.
It is possible that this could still hold 1.53+ support lows from a few weeks ago, but I'm not going to stick around to see what happens, but instead take a small profit and move forward. This poses a high risk of dropping much lower again in the short term, so it is basically why I'm suggesting to exit this.
***I'm on the sidelines for the time being and will wait to see if another opportunity to enter lower happens on ORPN, along with soon looking at other stocks.
ORPN had earlier provided plenty of opportunity for good entry in 1.50's-1.60's area (with suggestion of 1.66 Limit entry) this weeks action, so anyone following should be able to scrape out with a profit or at least break even.
It's ironic how the LABU - biotech index has been tearing it up the last few weeks at the same time while ORPN has been sitting sideways with slight upside at the same time... Oh well---- that's trading.
Recent ENLV News
- Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form F-3 - Registration statement by foreign private issuers • Edgar (US Regulatory) • 04/21/2026 08:15:57 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/21/2026 12:32:01 PM
- Enlivex Announces Second Regulatory Approval for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis • GlobeNewswire Inc. • 04/21/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/08/2026 12:33:27 PM
- Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares • GlobeNewswire Inc. • 04/08/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 12:32:01 PM
- Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt • GlobeNewswire Inc. • 03/26/2026 12:30:00 PM
- Enlivex shares jump after earnings as treasury gains boost results • IH Market News • 03/25/2026 03:05:33 PM
- Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] • Edgar (US Regulatory) • 03/25/2026 12:40:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/25/2026 12:31:00 PM
- Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48 • GlobeNewswire Inc. • 03/25/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/24/2026 12:34:59 PM
- Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/23/2026 12:02:14 PM
- Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis • GlobeNewswire Inc. • 03/23/2026 12:00:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/20/2026 08:05:23 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:14:20 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/13/2026 08:17:47 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/23/2026 01:00:15 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/10/2026 01:02:52 PM
- New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange • GlobeNewswire Inc. • 02/10/2026 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/05/2026 12:50:49 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 01/26/2026 01:01:50 PM
